login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock News
USA
- NYSE:TEVA -
US8816242098
-
ADR
19.78
USD
-0.33 (-1.64%)
Last: 10/15/2025, 7:00:00 PM
19.78
USD
0 (0%)
After Hours:
10/15/2025, 7:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
TEVA Latest News, Press Relases and Analysis
All
Press Releases
10 hours ago - By: Benzinga
- Mentions:
XBI
IBB
JAZZ
SPRC
...
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
2 days ago - By: Zacks Investment Research
- Mentions:
SNY
ALLO
CMMB
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
3 days ago - By: The Motley Fool
- Mentions:
NVDA
PLTR
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026
5 days ago - By: Teva Pharmaceutical Industries Ltd
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
21 days ago - By: Benzinga
Is Teva Pharmaceutical Indus Gaining or Losing Market Support?
2 months ago - By: Stocktwits
- Mentions:
IYLD
DFAX
This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More
5 days ago - By: Teva Pharmaceutical Industries Ltd
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
5 days ago - By: Zacks Investment Research
- Mentions:
JNJ
AMGN
KVUE
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
10 days ago - By: The Motley Fool
- Mentions:
PLTR
NVDA
TSM
Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters
13 days ago - By: Zacks Investment Research
- Mentions:
SNY
FOLD
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
15 days ago - By: Zacks Investment Research
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
15 days ago - By: Zacks Investment Research
- Mentions:
RDY
ALVO
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
20 days ago - By: Teva Pharmaceutical Industries Ltd
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
20 days ago - By: Teva Pharmaceutical Industries Ltd
Teva Releases Q3 2025 Aide Memoire
20 days ago - By: Teva Pharmaceutical Industries Ltd
Teva Releases Q3 2025 Aide Memoire
20 days ago - By: Teva Pharmaceutical Industries Ltd
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
25 days ago - By: Teva Pharmaceutical Industries Ltd
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
25 days ago - By: Teva Pharmaceutical Industries Ltd
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
25 days ago - By: Teva Pharmaceutical Industries Ltd
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
25 days ago - By: Teva Pharmaceutical Industries Ltd
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
a month ago - By: Teva Pharmaceutical Industries Ltd
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
a month ago - By: Teva Pharmaceutical Industries Ltd
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
a month ago - By: Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy
a month ago - By: Zacks Investment Research
- Mentions:
RDY
ALVO
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
a month ago - By: Teva Pharmaceutical Industries Ltd
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
a month ago - By: Zacks Investment Research
- Mentions:
SNY
BMY
NVO
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
a month ago - By: Teva Pharmaceutical Industries Ltd
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
a month ago - By: Teva Pharmaceutical Industries Ltd
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
2 months ago - By: Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY
2 months ago - By: Investor's Business Daily
- Mentions:
NVO
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
2 months ago - By: Teva Pharmaceutical Industries Ltd
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
2 months ago - By: Teva Pharmaceutical Industries Ltd
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
2 months ago - By: Yahoo Finance
Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)
2 months ago - By: Zacks Investment Research
- Mentions:
JNJ
AMGN
KVUE
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
Please enable JavaScript to continue using this application.